Preliminary clinical trials confirm the effectiveness of AD treatment by replacement of the patient’s serum albumin with its pharmacological preparation via plasmapheresis (plasma exchange (PE)) [22,27]. The gene discussed is ALB; the disease is Alzheimer disease.